<DOC>
	<DOC>NCT02862106</DOC>
	<brief_summary>The purpose is to evaluate efficacy and safety of therapeutic HBV vaccine (mimogen-based) treatment in chronic hepatitis B patients and to explore the most effective dosage and provide the rational for optimal dosing schedule.</brief_summary>
	<brief_title>Second Stage:Open-label Study of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B</brief_title>
	<detailed_description>Second stage(76-144 weeks): In this follow-up stage the trial is open designed, and all the subjects completed the first stage study(0-76 weeks) 1. Subjects with virological response but no serological response/with serological response but no virological response/neither virological nor serological response in the first stage, and be willing to continue the this follow-up study, will be treated by εPA-44 900 μg at week 80,83,86,89,92,95,98,101,104,108,112,116,120,124,128. 2. Subjects with both virological and serological response, will be followed-up to 144 weeks with no Adefovir Dipivoxil or εPA-44 900 μg treatment. The definition of response as below: 1. Virological response: HBV DNA＜2.93×10∧3IU/ml at 76 weeks; 2. Serological response: serological conversion of HBeAg at 76 weeks.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1. The subjects completed the first stage study(076 weeks) and willing to willing to participate in the trial 2. Uses effective contraception for subject with childbearing potential (including females and female partners of males) 3. Understands and signs ICF approved by EC 4. Willing to comply with the study procedures and complete the study 1.Any other factors inappropriate for enrollment in the study or study completion in the view of the investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>HBeAg positive</keyword>
	<keyword>Therapeutic HBV Vaccine</keyword>
	<keyword>HBV-specific Cytotoxic T Lymphocyte</keyword>
</DOC>